Liposomal Amphotericin B and Flucytosine for Talaromycosis in HIV/AIDS patients
Official title: Liposomal Amphotericin B and Flucytosine Antifungal Strategies for Talaromycosis (LAmB-FAST)
Funded at Duke University · NIH-11540350 · Data updated 2026-11-12
A study tests safer, more effective antifungal treatment options for talaromycosis in people with HIV/AIDS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | August 16, 2024 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $531,188 |
| NIH project number | 3R01AI181764-03S1 |
| Project ID | NIH-11540350 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with talaromycosis who are living with HIV/AIDS and are receiving treatment.
✕Less likely to help
Patients without talaromycosis or without HIV/AIDS involvement may not benefit from this antifungal-focused trial.
What this research studies
This project will test three strategies in one clinical trial to improve outcomes for talaromycosis, a fungal infection seen in people with HIV/AIDS. Researchers will compare a high-dose single infusion of liposomal amphotericin B to the standard 14-day regimen, add flucytosine to the regimens, and use HIV viral load to guide when to stop maintenance therapy. The trial builds on prior experience and aims to reduce mortality and treatment-related toxicity. Participants will be closely monitored for treatment response and side effects.
Why it matters
Potential benefit: If successful, patients could receive a safer, more effective treatment regimen with fewer side effects and better survival.
How similar studies have gone: Previous studies in similar fungal infections suggest that liposomal formulations can reduce toxicity while maintaining effectiveness, guiding this trial.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Le, Thuy — Duke University
- Study coordinator: Le, Thuy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.